Fate of the dominant follicle, embryonal survival, and pregnancy rates in dairy cattle treated with prostaglandin F2 alpha and progestins in the absence or presence of a functional corpus luteum.
Our objective was to examine the role of progestin type on serum concentrations of progesterone (p4) and estradiol-17 beta (E2), ovarian follicular dynamics, and fertility in cattle in the presence or absence of a corpus luteum (CL) in an estrus synchronization scheme using progestin and PGF2 alpha. In Exp. 1, 325 cows and heifers were given one injection of PGF2 alpha (d 0) and then assigned randomly within parity to five treatments: to receive a second PGF2 alpha injection 14 d later (control); to receive norgestomet (NORG) for 7 d beginning on d 8, with a second PGF2 alpha injection given either 1 d (NORG + no CL) or 6 d (NORG + CL) after insertion; or to receive a P4-releasing intravaginal device (PRID) in lieu of norgestomet at comparable times. Presence or absence of a CL was based on concentrations of serum P4 on d 14. Pregnancy rates after insemination were greater (P < .01) with luteal treatments than with nonluteal treatments. Embryonal survival between two stages of pregnancy was 87.6%. In Exp. 2, ovarian structures in 50 cows were examined daily using ultrasonography and the same five treatments. Diameter of the ovulatory follicle was greater (P < .05) with the nonluteal treatments (NORG and PRID + no CL) than with the control and luteal treatments (PRID and NORG + CL). Replacement of the dominant follicle during progestin treatment was altered by treatment (luteal status) and stage of the estrous cycle. Fertility was not enhanced by exogenous progestins when a CL was present. In the absence of a CL, progestin (P4 less than NORG at the doses used) reduced fertility by increasing E2 and the diameter of the ovulatory follicle and decreasing turnover of dominant follicles.
Smith
M W
MW
Department of Animal Sciences and Industry, Kansas State University, Manhattan 66506-0201, USA.
Stevenson
J S
JS
D000282:Administration, Intravaginal; D000818:Animals; D002417:Cattle / Q000097:blood / Q000502:physiology*; D003338:Corpus Luteum / Q000187:drug effects / Q000502:physiology*; D015237:Dinoprost / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004622:Embryo, Mammalian / Q000187:drug effects / Q000502:physiology*; D004958:Estradiol / Q000097:blood; D004973:Estrus Synchronization; D005260:Female; D005298:Fertility / Q000187:drug effects / Q000502:physiology; D005498:Follicular Phase / Q000502:physiology; D007315:Insemination, Artificial / Q000662:veterinary; D006080:Ovarian Follicle / Q000187:drug effects / Q000502:physiology*; D011247:Pregnancy; D018873:Pregnancy Rate; D011282:Pregnenediones / Q000494:pharmacology; D011374:Progesterone / Q000097:blood; D045167:Progesterone Congeners / Q000494:pharmacology; D011372:Progestins / Q000494:pharmacology*
D011282:Pregnenediones; D045167:Progesterone Congeners; D011372:Progestins; C100284:norgestomet; D011374:Progesterone; D004958:Estradiol; D015237:Dinoprost